Resultados globales: 2 registros encontrados en 0.01 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
1.
7 p, 657.6 KB Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations / Cortellini, Alessio (Imperial College London) ; Ricciuti, Biagio (Lowe Center for Thoracic Oncology. Dana Farber Cancer Institute) ; Vaz, Victor R. (Lowe Center for Thoracic Oncology. Dana Farber Cancer Institute) ; Soldato, Davide (Cancer Medicine Department. Gustave Roussy) ; Alessi, Joao V. (Lowe Center for Thoracic Oncology. Dana Farber Cancer Institute) ; Dall'olio, Filippo G. (Cancer Medicine Department. Gustave Roussy) ; Banna, Giuseppe L. (Candiolo Cancer Institute. FPO-IRCCS) ; Muthuramalingam, Sethupathi (Oncology Department. United Lincolnshire Hospital NHS Trust) ; Chan, Samuel (Oncology Department. Queen Alexandra University Hospital. Portsmouth Hospitals NHS Trust) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Piedra, Aida (Institut d'Investigació Biomèdica Sant Pau) ; Lamberti, Giuseppe (Department of Experimental Diagnostic and Specialty Medicine. S. Orsola-Malpighi University Hospital. Alma Mater Studiorum University of Bologna) ; Andrini, Elisa (Department of Experimental Diagnostic and Specialty Medicine. S. Orsola-Malpighi University Hospital. Alma Mater Studiorum University of Bologna) ; Addeo, Alfredo (Medical Oncology. University Hospital of Geneva) ; Friedlaender, Alex (Medical Oncology. University Hospital of Geneva) ; Facchinetti, Francesco (Université Paris-Saclay) ; Gorriá, Teresa (Hospital Clínic i Provincial de Barcelona) ; Mezquita, Laura (Hospital Clínic i Provincial de Barcelona) ; Hoton, Delphine (Department of Pathology. Cliniques Universitaires Saint-Luc) ; Valerie, Lacroix (Department of Cardiovascular and Thoracic Surgery. IREC. Cliniques Universitaires Saint-Luc) ; Nana, Frank Aboubakar (Institut de Recherche Expérimentale et Clinique (IREC). Pôle de Pneumologie. ORL et Dermatologie (PNEU). Université Catholique de Louvain (UCLouvain)) ; Artingstall, James (Bristol Haematology and Oncology Centre) ; Comins, Charles (Bristol Haematology and Oncology Centre) ; Di Maio, Massimo (Department of Oncology. University of Turin and Mauriziano Hospital) ; Caglio, Andrea (Department of Oncology. University of Turin and Mauriziano Hospital) ; Cave, Judith (Department of Medical Oncology. University Hospital Southampton NHS Foundation Trust) ; McKenzie, Hayley (Department of Medical Oncology. University Hospital Southampton NHS Foundation Trust) ; Newsom-Davis, Thomas (Department of Oncology. National Centre for HIV Malignancies. Chelsea and Westminster Hospital) ; Evans, Joanne S. (Imperial College London) ; Tiseo, Marcello (Medical Oncology Unit. University Hospital of Parma) ; D'Alessio, Antonio (Department of Biomedical Sciences. Humanitas University) ; Fulgenzi, Claudia A.M. (Department of Medical Oncology. University Campus Bio-Medico) ; Besse, Benjamin (School of Medicine. University Paris-Saclay) ; Awad, Mark M. (Lowe Center for Thoracic Oncology. Dana Farber Cancer Institute) ; Pinato, David J. (Division of Oncology. Department of Translational Medicine. University of Piemonte Orientale)
Introduction It has been recognized that increasing body mass index (BMI) is associated with improved outcome from immune checkpoint inhibitors (ICIs) in patients with various malignancies including non-small cell lung cancer (NSCLC). [...]
2022 - 10.1136/jitc-2021-004374
Journal for immunotherapy of cancer, Vol. 10 Núm. 2 (February 2022) , p. e004374  
2.
14 p, 4.6 MB A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer / Lazar, Vladimir (Gustave-Roussy Cancer Center (France)) ; Rubin, Eitan (Ben-Gurion University of the Negev (Israel)) ; Depil, Stephane (Leon Berard Cancer Center (France)) ; Pawitan, Yudi (Karolinska Institutet (Estocolm, Suècia)) ; Martini, Jean-François (Pfizer Oncology Research (USA)) ; Gomez-Navarro, Jesus (Takeda Pharmaceuticals International Co.(USA)) ; Yver, Antoine (AstraZeneca Pharmaceuticals LP (USA)) ; Kan, Zhengyin (Pfizer Oncology Research (USA)) ; Dry, Jonathan R. (AstraZeneca Pharmaceuticals LP (USA)) ; Kehren, Jeanne (Sanofi (France)) ; Validire, Pierre (Institut Mutualiste Montsouris (France)) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Vielh, Philippe (Gustave-Roussy Cancer Center (France)) ; Ducreux, Michel (Gustave-Roussy Cancer Center (France)) ; Galbraith, Susan (AstraZeneca Pharmaceuticals LP (USA)) ; Lehnert, Manfred (Takeda Pharmaceuticals International Co. (USA)) ; Onn, Amir (Chaim Sheba Medical Center (Israel)) ; Berger, Raanan (Chaim Sheba Medical Center (Israel)) ; Pierotti, Marco A. (Fondazione IRCCS Istituto Nazionale dei Tumori (Italy)) ; Porgador, Angel (Ben-Gurion University of the Negev (Israel)) ; Pramesh, C. S. (Tata Memorial Centre (India)) ; Ye, Ding-wei (Fudan University Shanghai Cancer Center (China)) ; Carvalho, Andre L. (Barretos Cancer Hospital. Fundacao Pio XII (Brazil)) ; Batist, Gerald (Jewish General Hospita. Segal Cancer Centre (Canada)) ; Le Chevalier, Thierry (Gustave-Roussy Cancer Center (France)) ; Morice, Philippe (Gustave-Roussy Cancer Center (France)) ; Besse, Benjamin (Gustave-Roussy Cancer Center (France)) ; Vassal, Gilles (Gustave-Roussy Cancer Center (France)) ; Mortlock, Andrew (AstraZeneca Pharmaceuticals LP (USA)) ; Hansson, Johan (Karolinska Institutet (Estocolm, Suècia)) ; Berindan Neagoe, Ioana (Universitatea de Medicină şi Farmacie Iuliu Haţieganu Cluj-Napoca (Romania)) ; Dann, Robert (General Electric Healthcare (USA)) ; Haspel, Joel (Oracle Corporation (UK)) ; Irimie, Alexandru (Universitatea de Medicină şi Farmacie Iuliu Haţieganu Cluj-Napoca (Romania)) ; Laderman, Steve (Agilent Technologies (USA)) ; Nechushtan, Hovav (Hadassah Hebrew University Medical Center (Israel)) ; Al Omari, Amal S. (King Hussein Cancer Center (Jordan)) ; Haywood, Trent (Blue Cross Blue Shield Association (USA)) ; Bresson, Catherine (WIN Consortium (France)) ; Soo, Khee Chee (National Cancer Centre (Singapore)) ; Osman, Iman (New York University Langone Medical Center (USA)) ; Mata, Hilario (MD Anderson Cancer Center (USA)) ; Lee, Jack J. (MD Anderson Cancer Center (USA)) ; Jhaveri, Komal (New York University Langone Medical Center (USA)) ; Meurice, Guillaume (Gustave-Roussy Cancer Center (France)) ; Palmer, Gary (Foundation Medicine Inc. (USA)) ; Lacroix, Ludovic (Gustave-Roussy Cancer Center (France)) ; Koscielny, Serge (Gustave-Roussy Cancer Center (France)) ; Eterovic, Karina Agda (MD Anderson Cancer Center (USA)) ; Blay, Jean-Yves (Leon Berard Cancer Center (France)) ; Buller, Richard (Pfizer Oncology Research (USA)) ; Eggermont, Alexander (Gustave-Roussy Cancer Center (France)) ; Schilsky, Richard L. (American Society of Clinical Oncology (USA)) ; Mendelsohn, John (MD Anderson Cancer Center (USA)) ; Soria, Jean-Charles (Gustave-Roussy Cancer Center (France)) ; Rothenberg, Mace (Pfizer Oncology Research (USA)) ; Scoazec, Jean-Yves (Gustave-Roussy Cancer Center (France)) ; Ki Hong, Waun (MD Anderson Cancer Center (USA)) ; Kurzrock, Razelle (Moores Cancer Center (USA)) ; Universitat Autònoma de Barcelona
Non-small cell lung cancer (NSCLC) is a leading cause of death worldwide. Targeted monotherapies produce high regression rates, albeit for limited patient subgroups, who inevitably succumb. We present a novel strategy for identifying customized combinations of triplets of targeted agents, utilizing a simplified interventional mapping system (SIMS) that merges knowledge about existent drugs and their impact on the hallmarks of cancer. [...]
2015 - 10.18632/oncotarget.3741
Oncotarget, Vol. 6, no. 16 (June 2015) , p. 14139-14152  

Vea también: autores con nombres similares
1 Besse, B.
1 Besse, Bruno
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.